Sale!

Comprehensive Hereditary Cancer Panel 104 Genes Test

5,850 د.إ

-10%

The Comprehensive Hereditary Cancer Panel 104 Genes Test, available at DNA Labs UAE for a cost of 5850 AED, is a cutting-edge genetic screening tool designed to assess an individual’s risk for various types of hereditary cancers. This test examines 104 specific genes that have been scientifically linked to an increased risk of developing cancer, including but not limited to breast, ovarian, colorectal, and prostate cancers. By analyzing an individual’s DNA, the test identifies genetic mutations that could predispose them to cancer, enabling early detection strategies or preventive measures to be implemented. This comprehensive approach to genetic testing is crucial for individuals with a family history of cancer, offering them invaluable insights into their genetic health and empowering them with information to make informed decisions regarding their healthcare and lifestyle choices. DNA Labs UAE provides this service with the utmost confidentiality and support, ensuring that individuals receive comprehensive counseling and guidance throughout the testing process.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

COMPREHENSIVE HEREDITARY CANCER PANEL 104 Genes Test

Test Name: COMPREHENSIVE HEREDITARY CANCER PANEL 104 Genes Test

Components: Screens 104 genes

  • AIP
  • ALK
  • APC
  • ATM
  • BAP1
  • BARD1
  • BLM
  • BMPR1A
  • BRCA1
  • BRCA2
  • BRIP1
  • BUB1B
  • CDC73
  • CDH1
  • CDK4
  • CDKN1C
  • CDKN2A
  • CEBPA
  • CEP57
  • CHEK2
  • CYLD
  • DDB2
  • DICER1
  • DIS3L2
  • EGFR
  • EPCAM
  • ERCC2
  • ERCC3
  • ERCC4
  • ERCC5
  • EXT1
  • EXT2
  • EZH2
  • FANCA
  • FANCB
  • FANCC
  • FANCD2
  • FANCE
  • FANCF
  • FANCG
  • FANCI
  • FANCL
  • FANCM
  • FH
  • FLCN
  • GATA2
  • GPC3
  • HNF1A
  • HOXB13
  • HRAS
  • KIT
  • MAX
  • MEN1
  • MET
  • MLH1
  • MSH2
  • MSH6
  • MUTYH
  • NBN
  • NF1
  • NF2
  • NSD1
  • PALB2
  • PHOX2B
  • PMS1
  • PMS2
  • PPM1D
  • PRF1
  • PRKAR1A
  • PTCH1
  • PTEN
  • RAD51C
  • RAD51D
  • RB1
  • RECQL4
  • RET
  • RHBDF2
  • RUNX1
  • SBDS
  • SDHAF2
  • SDHB
  • SDHC
  • SDHD
  • SLX4
  • SMAD4
  • SMARCA4
  • SMARCB1
  • STK11
  • SUFU
  • TMEM127
  • TP53
  • TSC1
  • TSC2
  • VHL
  • WT1
  • WRN
  • XPA
  • XPC

Price: 5850.0 AED

Sample Condition: Blood

Report Delivery: 4 weeks

Method: Next Generation Sequencing

Test type: Cancer

Doctor: Physician, Oncologist

Test Department: MOLECULAR DIAGNOSTICS

Pre Test Information: A duly filled Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) is mandatory.

Test Details

The Comprehensive Hereditary Cancer Panel (104 Genes) test is a genetic test that analyzes a person’s DNA for mutations or changes in 104 genes that are associated with an increased risk of developing certain types of cancer. These genes include BRCA1, BRCA2, TP53, PTEN, and others.

The test is typically recommended for individuals with a personal or family history of cancer, especially if the cancer occurred at a young age or affected multiple family members. The results of the test can help identify individuals who are at an increased risk of developing cancer and may benefit from increased cancer screening, risk-reducing surgeries, or other preventative measures.

The test is performed using a small blood sample or saliva sample, and the results are usually available within a few weeks. The test may be covered by insurance, depending on the individual’s specific circumstances and insurance coverage.

It is important to note that a positive result on the test does not necessarily mean that an individual will develop cancer, but it does indicate an increased risk. It is also possible to have a negative result on the test and still develop cancer, as not all genetic mutations that increase cancer risk are included in the panel.

Genetic counseling is recommended before and after the test to help individuals understand the implications of the results and make informed decisions about their healthcare.

Test Name COMPREHENSIVE HEREDITARY CANCER PANEL 104 Genes Test
Components Screens 104 genes:*AIP, *ALK, *APC, *ATM,*BAP1, *BARD1, *BLM, *BMPR1A, *BRCA1, *BRCA2, *BRIP1, *BUB1B, *CDC73, *CDH1, *CDK4, *CDKN1C, *CDKN2A, *CEBPA, *CEP57, *CHEK2, *CYLD, *DDB2, *DICER1, *DIS3L2, *EGFR, *EPCAM ,*ERCC2, *ERCC3, *ERCC4, *ERCC5, *EXT1, *EXT2, *EZH2, *FANCA, *FANCB, *FANCC, *FANCD2, *FANCE, *FANCF, *FANCG, *FANCI, *FANCL, *FANCM, *FH, *FLCN, *GATA2, *GPC3, *HNF1A, *HOXB13, *HRAS, *KIT, *MAX, *MEN1, *MET, *MLH1, *MSH2, *MSH6, *MUTYH, *NBN, *NF1, *NF2, *NSD1, *PALB2, *PHOX2B, *PMS1, *PMS2, *PPM1D, *PRF1, *PRKAR1A, *PTCH1, *PTEN, *RAD51C, *RAD51D, *RB1, *RECQL4, *RET, *RHBDF2, *RUNX1, *SBDS, *SDHAF2, *SDHB, *SDHC, *SDHD, *SLX4, *SMAD4, *SMARCA4, *SMARCB1, *STK11, *SUFU, *TMEM127, *TP53, *TSC1, *TSC2, *VHL, *WT1, *WRN, *XPA, *XPC
Price 5850.0 AED
Sample Condition Blood
Report Delivery 4 weeks
Method Next Generation Sequencing
Test type Cancer
Doctor Physician, Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information A duly filled Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) is mandatory.
Test Details

The Comprehensive Hereditary Cancer Panel (104 Genes) test is a genetic test that analyzes a person’s DNA for mutations or changes in 104 genes that are associated with an increased risk of developing certain types of cancer. These genes include BRCA1, BRCA2, TP53, PTEN, and others.

The test is typically recommended for individuals with a personal or family history of cancer, especially if the cancer occurred at a young age or affected multiple family members. The results of the test can help identify individuals who are at an increased risk of developing cancer and may benefit from increased cancer screening, risk-reducing surgeries, or other preventative measures.

The test is performed using a small blood sample or saliva sample, and the results are usually available within a few weeks. The test may be covered by insurance, depending on the individual’s specific circumstances and insurance coverage.

It is important to note that a positive result on the test does not necessarily mean that an individual will develop cancer, but it does indicate an increased risk. It is also possible to have a negative result on the test and still develop cancer, as not all genetic mutations that increase cancer risk are included in the panel.

Genetic counseling is recommended before and after the test to help individuals understand the implications of the results and make informed decisions about their healthcare.